Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Clinical outcomes in patients with accelerated or blast-Phase MPN treated with triplet regimen of hypomethylating agent, JAK inhibitor, and venetoclax (HMA/JAKi/Ven): A multicenter case series

View Full Paper
Ask AI
Bookmark
Share

Authors

EREllen K. Ritchie

Discussion

Loading...

Member takes

Overview

Case series shows 55% response rates in patients with MPN-AP/BP treated with hypomethylating agents and JAK inhibitors, highlighting poor survival outcomes.

Key Points

  • To evaluate the clinical outcomes of triplet therapy HMA/JAKi/Ven in patients with MPN in accelerated or blast phase.
  • Retrospective case series of MPN-AP/BP patients from two centers (Weill Cornell and MSKCC)
  • Patients were treated with hypomethylating agents (HMA), JAK inhibitors (JAKi), and venetoclax
  • Diagnosis and response assessed via electronic medical records and ELN criteria
  • Overall survival (OS) and progression-free survival (PFS) were calculated using the Kaplan–Meier method.
  • Overall response rate (ORR) was 55%, with 18.2% complete response (CR) and 9.1% partial response (PR)
  • Median OS was 3.5 months with a favorable OS of 15.8 months in responders
  • Progression-free survival (PFS) favored responders at 14.8 months compared to non-responders' 3.06 months
  • Patients with high WBC and favorable cytogenetics showed potential for favorable outcomes.

Cite This Study

Ellen K. Ritchie (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7a7https://doi.org/10.1182/blood-2025-2026
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Evaluation of hypomethylating agents with or without venetoclax in patients with accelerated phase and blast phase myeloproliferative neoplasms: a HERO consortium study2026
  2. 2Real-world use of venetoclax and hypomethylating agents (HMA) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): A multi-institutional case series2025 · 1 citations
  3. 3Outcome of patients with accelerated and blast‐phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination—A FIM study2025 · 3 citations
  4. 4Outcomes of blast-phase MPN and JAK2, MPL, and CALRmutated de novo AML: A propensity score-adjusted cohort study.2024
  5. 5Venetoclax and decitabine in myeloproliferative neoplasm-blast Phase (MPN-BP): Results of enable, a gimema and airc-mynerva multicenter, Phase 2 trial2025 · 5 citations